A sustained absorption theophylline-containing pellet for oral administration comprises a core of theophylline or a pharmacological equivalent thereof and an organic acid embedded in a polymeric material in a multi-layer arrangement and an outer membrane which permits release of the theophylline at a controlled rate in an aqueous medium. The pellet has a dissolution rate in vitro in an aqueous medium, which when measured in a basket assembly according to u.S. Pharmacopoeia xx at 37°C and 75 r.p.m., is not more than 15% of the total theophylline after 2 hours of measurement in a buffer solution at ph 7.5. Not more than 35% of the total theophylline is released after a total of 7 hours of measurement and not more than 65% of the total theophylline is released after a total of 13 hours.
|
1. A sustained absorption active ingredient-containing pellet for oral administration, said pellet comprising a core of an active ingredient selected from the group consisting of anhydrous theophylline, aminophylline, dyphylline, theophylline calcium salicylate and theophylline sodium glycinate and an organic acid selected from the group consisting of citric acid, tartaric acid, succinic acid, malic acid, ascorbic acid and fumaric acid or a mixture thereof embedded in a polymeric material which contains a major proportion of a water-soluble polymer and a membrane of a film-forming polymer or mixture thereof surrounding the core whereby said active ingredient is released at a controlled rate in an aqueous medium and said pellet has a dissolution rate in an aqueous medium which is substantially independent of ph and which when measured is a basket assembly according to u.S. Pharmacopoeia xx at 37°C and 75 r.p.m., in a buffer solution at ph 7.5 has the following characteristics:
(a) from 0 to 15% of said active ingredient is released after two hours of measurement in said assembly; (b) from 15 to 35% of said active ingredient is released after 7 hours of measurement in said assembly; (c) from 45 to 65% of said active ingredient is released after 13 hours of measurement in said assembly; and (d) from 80 to 100% of said active ingredient is released after 24 hours of measurement in said assembly.
2. A pellet according to
3. A pellet according to
4. A pellet according to
5. A pellet according to
6. A pellet according to
7. A pellet according to
8. A pellet according to
9. A pellet according to
10. A pellet according to
11. A pellet according to
12. A pellet according to
13. A pellet according to
14. A capsule comprising pellets according to
15. A tablet comprising pellets according to
16. A pellet according to
17. A pellet according to
|
This application is a continuation of application Ser. No. 870,293, filed May 21, 1986, now U.S. Pat. No. 4,663,150, which is a continuation of application Ser. No. 597,716 filed Apr. 6, 1984, now abandoned.
1. Field of the Invention
This invention relates to sustained absorption pharmaceutical compositions and, in particular, to a sustained absorption theophylline composition.
2. Description of the Prior Art
Theophylline (1,3-dimethylxanthine) has a pharmacological activity similar to that of the other xanthine derivatives, caffeine and theobromine. The diuretic action of theophylline though stronger than that of caffeine is of short duration. Theophylline is a more powerful relaxant of involuntary muscle than either theobromine or caffeine. Theophylline is primarily used as a bronchosphasm relaxant or bronchodilator in bronchosphasm associated with asthma, chronic bronchitis and emphysema.
Theophylline has been found to have a minimum effective plasma concentration of about 5 mcg/ml and an average therapeutic concentration of about 10 mcg/ml. The therapeutic range of concentration of theophylline is generally regarded in practice as 10-20 mcg/ml, levels below 10 mcg/ml being ineffective and levels above 20 mcg/ml being toxic.
The apparent biological half-life of theophylline has been found to range from 4-9 hours.
Preparations of anhydrous theophylline require a dosage regimen of 150-500 mg orally every six hours for adults.
For this reason, a number of slow or sustained release forms of theophylline have been developed and include: THEOGRAD, which is marketed by Abbott Laboratories Limited and comes in 350 mg tablets and is administered at a rate of one tablet per 12 hours; THEO-DUR, marketed by Fisons Limited and which comes in 200 mg and 300 mg tablets and is administered 12 hourly, initially 200-300 mg, increasing by 100-150 mg until a sufficient therapeutic effect is obtained; and UNIPHYLLIN UNICONTIN, marketed by Napp Laboratories Limited which comes in 200 mg tablets, with three or four tablets being taken as a single daily dose, following initial therapy of two daily given as a once or twice daily dosage with subsequent increments as necessary until a sufficient therapeutic effect is obtained.
With each slow-release form of theophylline the dose is increased until the required therapeutic effect is obtained, this is known as a titration standard.
An effective slow or sustained release form of theophylline suitable for once daily administration must be capable of maintaining the plasma concentration of theophylline within the range of 10-20 mcg/ml over 24 hours. Only a product with a Cmax/Cmin at 24 hours ratio of 2:1 or less could maintain levels within this range 24 hours after administration.
It is an object of the present invention to provide a sustained absorption form of theophylline which is suitable for once daily administration and which gives a consistent Cmax/Cmin ratio at 24 hours of 2:1 or less.
Accordingly, the invention provides a sustained absorption active ingredient-containing pellet for oral administration, said pellet comprising a core of an active ingredient selected from the group consisting of anhydrous theophylline, aminophylline, dyphylline, theophylline calcium salicylate and theophylline sodium glycinate and an organic acid selected from the group consisting of citric acid, tartaric acid, succinic acid, malic acid, ascorbic acid and fumaric acid or a mixture thereof embedded in a polymeric material which contains a major proportion of a water-soluble polymer and membrane of a film-forming polymer or mixture thereof surrounding the core whereby said active ingredient is released at a controlled rate in an aqueous medium and said pellet has a dissolution rate in an aqueous medium which is substantially independent of pH and which when measured in a Basket Assembly according to U.S. Pharmacopoeia XX at 37°C and 75 r.p.m., in a buffer solution at pH 7.5 has the following characteristics:
(a) from 0 to 15% of said active ingredient is released after two hours of measurement in said assembly;
(b) from 15 to 35% of said active ingredient is released after 7 hours of measurement in said assembly;
(c) from 45 to 65% of said active ingredient is released after 13 hours of measurement in said assembly; and
(d) from 80 to 100% of said active ingredient is released after 24 hours of measurement in said assembly.
As used herein "theophylline" means theophylline or a derivative or salt thereof. Suitable forms of theophylline for use in the pellets according to the invention are anhydrous theophylline, aminophylline, dyphylline, theophylline calcium salicylate and theophylline sodium glycinate.
Preferably, the organic acid is selected from one or more of the following acids: citric acid, tartaric acid, succinic acid, malic acid, ascorbic acid and fumaric acid.
The theophylline and organic acid are preferably present in a ratio of 4:1.
Preferably, the polymeric material in which the theophylline is embedded includes a major proportion of a water-soluble polymer.
The polymeric material may consist solely of a water soluble polymer or, alternatively, it may include a minor proportion of a water insoluble polymer. Suitably, the water soluble and water insoluble polymers will be present in a ratio of 9:1.
The water soluble polymer is suitably hydroxypropylmethylcellulose, polyvinylpyrrolidone or a polymer sold under the trade mark EUDRAGIT RL. Polymers sold under the Trade Mark EUDRAGIT are acrylic resins comprising co-polymers of acrylic and methacrylic acid esters with a low content of quaternary ammonium groups and are described in the "Eudragit" brochure of Rohm Pharma GmbH (1982) wherein detailed physical-chemical data of these products is given. The ammonium groups are present as salts and give rise to permeability of the lacquer films. Eudragit RL and RS are freely permeable (RL) or slightly permeable (RS), respectively independent of pH.
The water insoluble polymer is suitably a cellulose ether such as methyl-, ethyl- or propylcellulose, shellac or a polymer sold under the trade mark EUDRAGIT RS. Shellac is a resinous excretion of the insect Laccifer (Tachardia) Lacca Kerr, order Homoptera, family Coccidae.
The core will suitably have between 20 and 120 layers and is built up in a manner known per se.
Further, preferably, the multi-layer arrangement of theophylline, organic acid and polymeric material will be built up on a central inert core suitably consisting of a non-pareil seed having an average diameter in the range 0.3-0.7 mm.
The membrane preferably includes a major proportion of a water insoluble polymer.
Further, the membrane suitably comprises a major proportion of a water insoluble polymer and a minor proportion of a water soluble polymer, the ratio of water insoluble to water soluble polymer being determined by the inherent solubility characteristics of the polymers selected.
Suitable combinations of water insoluble and water soluble polymers for the membrane include: ethylcellulose and hydroxypropylmethylcellulose in a ratio of 9:1; EUDRAGIT RS and EUDRAGIT RL in a ratio of 8:2 and shellac and polyvinylpyrrolidone in a ratio of 9:1.
The pellets may be filled into hard gelatin capsules or compressed into tablets using a binder and/or hardening agent commonly employed in tabletting such as microcrystalline cellulose sold under the trade mark AVICEL or a co-crystallized powder of highly modified dextrins (3% by weight) and sucrose sold under the trade mark DI-PAC, in such a way that the specific dissolution rate of the pellets is maintained.
The invention will be further illustrated by the following Examples.
Theophylline-containing pellets were prepared in the following manner.
Anhydrous theophylline (#100 mesh)(3,500 g), talc (438 g) and citric acid (875 g) were blended in a standard pharmaceutical blender into a uniform powder.
A solution of 5% hydroxypropylmethylcellulose in methanol/methylene chloride, 60:40 was prepared.
The membrane solution was prepared from the following ingredients:
One part (by volume) 10% hydroxypropylmethylcellulose (15 c.p.s.) in methanol/methylene chloride, 60:40;
Nine parts (by volume) 10% ethylcellulose (50 c.p.s.) in methanol/methylene chloride, 60:40;
Ten parts (by volume) methanol/methylene chloride, 60:40;
Ten parts (by weight) talc;
Diethylphthalate (plasticizer), as required.
Step 1. 500 g of starch/sugar seeds (0.4 to 0.5 mm diameter) were placed in a conventional coating pan and rotation was commenced.
Step 2. The seeds were wetted with sufficient polymer solution (b) to dampen them uniformly.
Step 3. Powder blend (a) was dusted on until no more adhered to the dampened seeds.
Step 4. The powder coated seeds were allowed to dry (5-15 minutes).
Steps 2-4 were repeated until all of the powder (a) had been coated on.
Step 5. The powder coated seeds were sealed with one application of polymer solution (b) and talc.
Step 6. The powder coated seeds were dried at 45°-50°C for at least 12 hours.
Step 7. The powder coated seeds were placed in a conventional coating pan and rotation was commenced.
Step 8. A coat of membrane solution (c) was applied to the powder coated seeds and the seeds so coated were allowed to dry. A coat of membrane solution (c) corresponds to 10 ml of solution (c) per 1,000 g of coated seeds.
Step 9. Two further coats of membrane solution (c) were applied to the coated seeds.
Step 10. The finished pellets were allowed to dry at 45°-50° C.
The dired pellets were subjected to a dissolution test as follows:
Apparatus:
A Basket Assembly as described in the United States Pharmacopoeia XX at 37°C and 75 r.p.m.
Buffer:
25 ml of 2.0M potassium chloride and 950 ml of water was adjusted to pH 7.5 with either 0.1N hydrochloric acid or 0.1N sodium hydroxide and the volume made up to 1,000 ml with water.
Sampling Times:
2, 7, 13 and 24 hours.
Method:
1 g of finished pellets was placed in the basket of the assembly and rotation was commenced in the buffer. At the sampling times, 1.0 ml of the solution was removed and diluted to 50 ml with 0.1M hydrochloric acid. The absorbance of the sample was measured at 270 nm in a spectrophotometer.
The absorbance value equivalent to 100% dissolution was determined by grinding 1 g of pellets in 0.1M hydrochloric acid, diluting to 1,000 ml with water, further diluting a 1 ml sample to 50 ml with water and reading at 270 nm as above. The percentage dissolution was calculated by division.
Steps 7 to 10 were repeated until the dissolution rate at pH 7.5 was as follows:
______________________________________ |
2 hours |
0-15% |
7 hours |
15-35% |
13 hours |
45-65% |
24 hours |
80-100% |
______________________________________ |
Theophylline-containing pellets were prepared in the following manner.
Anhydrous theophylline (#100 mesh)(3,500 g), talc (438 g) and tartaric acid (875 g) were blended in a standard pharmaceutical blender into a uniform powder.
A solution of nine parts 6.25% EUDRAGIT RL in isopropanol/acetone, 60:40 and one part 6.25% EUDRAGIT RS in isopropanol/acetone, 60:40 was prepared.
The membrane solution was prepared from the following ingredients:
Two parts (by volume) 5% EUDRAGIT RL in isopropanol/acetone, 60:40;
Eight parts (by volume) 5% EUDRAGIT RS in isopropanol/acetone, 60:40;
Ten parts (by volume) isopropanol/acetone, 60:40;
Ten parts (by weight) talc;
Diethylphthalate (plasticizer), as required.
Steps 1-4 were carried out as in Example 1.
Steps 2-4 were repeated until all of the powder (a) had been coated on.
Step 5. The powder coated seeds were sealed with two applications of polymer solution (b) and talc.
Steps 6-8 were carried out as in Example 1. As in the case of Example 1 a coat of membrane solution (c) corresponds to 10 ml of solution (c) per 1,000 g of coated seeds.
Step 9. One further coat of membrane solution (c) was applied to the coated seeds.
Step 10. the finished pellets were allowed to dry at 45°-50° C.
The dried pellets were subjected to a dissolution test as described in Example 1 and Steps 7-10 were repeated until the desired dissolution rate at pH 7.5 was obtained.
Theophylline-containing pellets were prepared in the following manner.
Anhydrous theophylline (#100 mesh)(3,500 g), talc (438 g) and succinic acid (875 g) were blended in a standard pharmaceutical blender into a uniform powder.
A solution of 10% polyvinylpyrrolidone in isopropanol was prepared.
The membrane solution was prepared from the following ingredients:
One part (by volume) 20% polyvinylpyrrolidone (Kollidon K-30) in isopropanol;
Nine parts (by volume) 33% Shellac (dewaxed) in ethanol;
Ten parts (by volume) isopropanol;
Ten parts (by weight) talc;
Diethylphthalate (plasticizer), as required.
Steps 1-4 were carried out as in Example 1.
Steps 2-4 were repeated until all of the powder (a) had been coated on.
Steps 5-10 were carried out as in Example 1.
The dried pellets were then subjected to a dissolution test as described in Example 1 above. In addition, the dissolution rate was also measured at pH 3.0 and pH 6∅ Steps 7-10 were repeated until a satisfactory dissolution rate was obtained at each pH. A total of 20 coats of membrane solution (c) was applied before the required dissolution rate was obtained.
Table 1 gives the percentage dissolution observed at each pH after 15, 17, 18 and 20 coats of membrane solution (c) had been applied.
TABLE 1 |
______________________________________ |
Membrane Coats Dissolution (%) |
Applied Time (h) pH 3.0 6.0 7.5 |
______________________________________ |
15 2 14 17 17 |
7 60 66 68 |
13 95 98 100 |
24 100 100 100 |
17 2 10 10 11 |
7 40 43 45 |
13 76 80 84 |
24 100 100 100 |
18 2 6 8 7 |
7 35 42 39 |
13 67 73 71 |
24 100 100 100 |
20 2 5 7 7 |
7 25 28 30 |
13 52 56 58 |
24 86 90 94 |
______________________________________ |
It will be observed from Table 1 that the pecentage dissolution at pH 3.0 and 6.0 at each sampling time were within 8% of the corresponding figure obtained at pH 7.5. Accordingly, it will be appreciated that the dissolution rate of the pellets according to the invention is substantially pH independent.
FIG. 1 is a graph of percentage dissolution versus time of pellets according to the invention. Curve B shows the maximum percentage dissolution per unit time and curve A the minimum percentage dissolution per unit time permissible to achieve the desired plasma concentration Cmax/Cmin at 24 hours of 2:1 or less.
FIG. 2 is a graph of plasma levels (mcg/ml) versus time after administration (hours) for pellets prepared according to Example 3 (o) compared with two sustained release forms of theophylline currently on the market, namely THEO-DUR tablets (*) and UNIPHYLLIN UNICONTIN tablets (+).
The graphs of FIG. 2 were drawn from the mean values obtained for six subjects according to the data listed in Tables 2, 3 and 4.
TABLE 2 |
__________________________________________________________________________ |
Sustained-absorption theophylline pellets prepared according to Example |
Blood level study results - Summary of pharmacokinetic data |
__________________________________________________________________________ |
Plasma Levels (mcg/ml) |
HOURS AFTER ADMINISTRATION |
SUBJ 0.00 |
3.00 |
4.00 |
5.00 |
6.00 |
8.00 |
10.00 |
11.00 |
12.00 |
13.00 |
14.00 |
16.00 |
24.00 |
36.00 |
48.00 |
AUC** |
__________________________________________________________________________ |
1 0.00 |
1.67 |
2.64 |
3.38 |
4.24 |
6.70 |
6.86 |
6.71 |
7.02 |
6.04 |
6.36 |
6.62 |
6.36 |
3.69 |
1.64 |
219.54 |
2 0.00 |
1.12 |
1.76 |
3.04 |
5.06 |
5.99 |
6.86 |
7.62 |
7.38 |
7.15 |
7.49 |
6.59 |
4.13 |
1.36 |
0.51 |
163.91 |
3 0.00 |
1.37 |
1.85 |
2.95 |
3.82 |
4.41 |
4.44 |
4.72 |
5.25 |
5.31 |
4.32 |
5.30 |
4.82 |
1.10 |
0.00 |
138.41 |
4 0.00 |
1.59 |
2.10 |
2.57 |
4.85 |
7.05 |
8.38 |
8.38 |
8.31 |
9.00 |
7.99 |
8.22 |
6.07 |
1.84 |
0.61 |
207.01 |
5 0.00 |
1.34 |
1.83 |
2.88 |
4.10 |
4.91 |
5.29 |
4.71 |
4.53 |
4.37 |
4.40 |
4.19 |
3.30 |
1.10 |
0.00 |
118.65 |
6 0.00 |
1.34 |
6.97 |
13.83 |
13.06 |
12.58 |
10.77 |
11.30 |
10.37 |
9.27 |
8.43 |
6.23 |
2.90 |
1.18 |
0.00 |
202.28 |
MEAN 0.00 |
1.41 |
2.86 |
4.78 |
5.86 |
6.94 |
7.10 |
7.24 |
7.14 |
6.86 |
6.50 |
6.19 |
4.60 |
1.71 |
0.46 |
174.97 |
ST DEV |
0.00 |
0.20 |
2.04 |
4.44 |
3.56 |
2.94 |
2.26 |
2.49 |
2.11 |
1.99 |
1.79 |
1.36 |
1.42 |
1.01 |
0.64 |
40.96 |
*CV (%) |
0.00 |
14.07 |
71.37 |
93.06 |
60.81 |
42.41 |
31.85 |
34.37 |
29.54 |
28.98 |
27.62 |
21.98 |
30.93 |
58.92 |
139.27 |
23.41 |
MAX 0.00 |
1.67 |
6.97 |
13.83 |
13.06 |
12.58 |
10.77 |
11.30 |
10.37 |
9.27 |
8.43 |
8.22 |
6.36 |
3.69 |
1.64 |
219.54 |
MIN 0.00 |
1.12 |
1.76 |
2.57 |
3.82 |
4.41 |
4.44 |
4.71 |
4.53 |
4.37 |
4.32 |
4.19 |
2.90 |
1.10 |
0.00 |
118.65 |
__________________________________________________________________________ |
MEAN OF NUMBER OF |
NUMBER OF |
CV VALUES |
ZERO POOR |
AT SAMPLE |
BLOOD ABSORBERS** |
POINTS LEVELS <10% AUC |
48.94 3 0 |
__________________________________________________________________________ |
HOURS COVER AT FOUR |
BLOOD LEVELS PEAKING |
PEAK C(MAX)/C(MIN) |
SUBJ 0.00 5.00 10.00 |
20.00 TIME HEIGHT AT 24.00 HOURS |
__________________________________________________________________________ |
1 48.00 |
23.49 0.00 0.00 12.00 7.02 1.10 |
2 48.00 |
15.20 0.00 0.00 11.00 7.62 1.85 |
3 48.00 |
7.40 0.00 0.00 13.00 5.31 1.10 |
4 48.00 |
20.90 0.00 0.00 13.00 9.00 1.48 |
5 48.00 |
2.03 0.00 0.00 10.00 5.29 1.60 |
6 48.00 |
15.30 7.89 0.00 5.00 13.83 4.77 |
MEAN 48.00 |
14.05 1.32 0.00 10.67 8.01 1.98 |
ST DEV 0.00 8.10 3.22 0.00 3.01 3.18 1.40 |
CV (%) 0.00 0.58 2.45 0.00 0.28 0.40 0.70 |
BASED ON MEAN BLOOD LEVEL CURVE |
MEAN 48.00 |
16.77 0.00 0.00 11.00 7.24 1.58 |
__________________________________________________________________________ |
*Coefficient of variation |
**Area under the curve. |
TABLE 3 |
__________________________________________________________________________ |
Theo-Dur SR tablets |
Blood level study results - Summary of pharmacokinetic data |
__________________________________________________________________________ |
Plasma Levels (mcg/ml) |
HOURS AFTER ADMINISTRATION |
SUBJ 0.00 |
3.00 |
4.00 |
5.00 |
6.00 |
8.00 |
10.00 |
11.00 |
12.00 |
13.00 |
14.00 |
16.00 |
24.00 |
36.00 |
48.00 |
AUC** |
__________________________________________________________________________ |
1 0.00 |
5.70 |
7.48 |
9.05 |
10.26 |
13.84 |
10.64 |
9.82 |
9.21 |
8.82 |
9.23 |
7.29 |
4.33 |
2.05 |
0.89 |
238.34 |
2 0.00 |
3.33 |
5.62 |
7.06 |
8.30 |
7.99 |
8.01 |
7.29 |
6.66 |
6.80 |
6.59 |
5.53 |
2.63 |
1.18 |
0.50 |
161.53 |
3 0.00 |
3.31 |
3.88 |
5.13 |
6.82 |
7.37 |
8.66 |
8.55 |
8.15 |
7.99 |
8.09 |
7.05 |
3.97 |
1.11 |
0.00 |
178.68 |
4 0.00 |
4.38 |
4.56 |
6.69 |
7.88 |
10.26 |
1.61 |
12.91 |
12.39 |
10.58 |
9.98 |
8.60 |
4.32 |
0.92 |
0.00 |
217.85 |
5 0.00 |
3.65 |
4.49 |
5.61 |
6.95 |
8.05 |
7.29 |
5.91 |
5.75 |
4.72 |
4.37 |
3.30 |
0.96 |
0.00 |
0.00 |
103.89 |
6 0.00 |
5.09 |
4.75 |
5.39 |
6.40 |
8.60 |
8.17 |
7.37 |
7.24 |
7.28 |
6.26 |
5.90 |
2.72 |
0.96 |
0.00 |
158.87 |
MEAN 0.00 |
4.24 |
5.13 |
6.49 |
7.77 |
9.35 |
9.06 |
8.64 |
8.23 |
7.70 |
7.42 |
6.28 |
3.16 |
1.04 |
0.23 |
176.53 |
ST DEV |
0.00 |
0.99 |
1.28 |
1.47 |
1.41 |
2.41 |
1.68 |
2.47 |
2.36 |
1.97 |
2.08 |
1.82 |
1.32 |
0.66 |
0.38 |
47.64 |
*CV (%) |
0.00 |
23.36 |
24.97 |
22.60 |
18.15 |
25.76 |
18.59 |
28.59 |
28.67 |
25.65 |
28.02 |
29.01 |
41.77 |
63.21 |
163.81 |
26.98 |
MAX 0.00 |
5.70 |
7.48 |
9.05 |
10.26 |
13.84 |
11.61 |
12.91 |
12.39 |
10.58 |
9.98 |
8.60 |
4.33 |
2.05 |
0.89 |
238.34 |
MIN 0.00 |
3.31 |
3.88 |
5.13 |
6.40 |
7.37 |
7.29 |
5.91 |
5.75 |
4.72 |
4.37 |
3.30 |
0.96 |
0.00 |
0.00 |
102.89 |
__________________________________________________________________________ |
MEAN OF NUMBER OF |
NUMBER OF |
CV VALUES |
ZERO POOR |
AT SAMPLE |
BLOOD ABSORBERS |
POINTS LEVELS <10% AUC |
38.73 5 0 |
__________________________________________________________________________ |
HOURS COVER AT FOUR |
BLOOD LEVELS PEAKING |
PEAK C(MAX)/C(MIN) |
SUBJ 0.00 5.00 10.00 |
20.00 TIME HEIGHT AT 24.00 HOURS |
__________________________________________________________________________ |
1 48.00 |
19.56 5.00 0.00 8.00 13.84 3.20 |
2 48.00 |
13.73 0.00 0.00 6.00 8.30 3.16 |
3 48.00 |
16.43 0.00 0.00 10.00 8.66 2.18 |
4 48.00 |
18.52 6.19 0.00 11.00 12.91 2.99 |
5 36.00 |
8.27 0.00 0.00 8.00 8.05 8.39 |
6 48.00 |
14.19 0.00 0.00 8.00 8.60 3.16 |
MEAN 46.00 |
15.12 1.86 0.00 8.50 10.06 3.85 |
ST DEV 4.90 4.07 2.91 0.00 1.76 2.59 2.26 |
CV (%) 0.11 0.27 1.56 0.00 0.21 0.26 0.59 |
__________________________________________________________________________ |
BASED ON MEAN BLOOD LEVEL CURVE |
MEAN 48.00 |
15.42 0.00 0.00 8.00 9.35 2.96 |
__________________________________________________________________________ |
*Coefficient of variation |
**Area under the curve |
TABLE 4 |
__________________________________________________________________________ |
Uniphylline Unicontin |
Blood level study results - Summary of pharmacokinetic data |
__________________________________________________________________________ |
Plasma Levels (mcg/ml) |
HOURS AFTER ADMINISTRATION |
SUBJ 0.00 |
4.00 |
4.00 |
5.00 |
6.00 |
8.00 |
10.00 |
11.00 |
12.00 |
13.00 |
14.00 |
16.00 |
24.00 |
36.00 |
48.00 |
AUC** |
__________________________________________________________________________ |
1 0.00 |
5.70 |
6.89 |
8.35 |
9.52 |
10.67 |
10.42 |
9.55 |
10.17 |
9.45 |
9.28 |
8.68 |
8.50 |
3.26 |
1.49 |
297.44 |
2 0.00 |
4.98 |
5.64 |
5.81 |
5.14 |
4.82 |
5.58 |
5.22 |
5.10 |
5.30 |
5.05 |
4.49 |
2.20 |
0.74 |
0.00 |
123.65 |
3 0.00 |
8.87 |
11.88 |
12.59 |
9.79 |
8.26 |
7.26 |
7.14 |
6.65 |
7.58 |
6.76 |
6.53 |
4.47 |
1.13 |
0.00 |
206.72 |
4 0.00 |
4.99 |
6.20 |
6.10 |
6.85 |
5.72 |
8.03 |
8.28 |
8.46 |
7.92 |
8.39 |
7.00 |
4.68 |
2.01 |
0.84 |
204.24 |
5 0.00 |
3.87 |
3.90 |
5.15 |
6.16 |
5.34 |
4.69 |
4.29 |
4.02 |
3.58 |
3.41 |
2.69 |
1.80 |
0.00 |
0.00 |
92.20 |
6 0.00 |
5.85 |
6.12 |
6.79 |
6.80 |
9.71 |
11.22 |
11.47 |
10.68 |
10.19 |
9.63 |
7.36 |
3.08 |
0.96 |
0.00 |
196.96 |
MEAN 0.00 |
5.71 |
6.77 |
7.47 |
7.38 |
7.42 |
7.87 |
7.66 |
7.51 |
7.34 |
7.09 |
6.13 |
4.12 |
1.35 |
0.39 |
186.87 |
ST DEV |
0.00 |
17.0 |
2.70 |
2.74 |
1.87 |
2.47 |
2.59 |
2.69 |
2.71 |
2.50 |
2.48 |
2.17 |
2.44 |
1.14 |
0.64 |
72.09 |
*CV (%) |
0.00 |
29.76 |
39.84 |
36.67 |
25.37 |
33.28 |
32.89 |
35.06 |
36.09 |
34.09 |
34.99 |
35.36 |
59.20 |
84.32 |
163.71 |
38.58 |
MAX 0.00 |
8.87 |
11.88 |
12.59 |
9.79 |
10.67 |
11.22 |
11.47 |
10.68 |
10.19 |
9.63 |
8.68 |
8.50 |
3.26 |
1.49 |
297.44 |
MIN 0.00 |
3.87 |
3.90 |
5.15 |
5.14 |
4.82 |
4.69 |
4.29 |
4.02 |
3.58 |
3.41 |
2.69 |
1.80 |
0.00 |
0.00 |
92.20 |
__________________________________________________________________________ |
MEAN OF NUMBER OF |
NUMBER OF |
CV VALUES |
ZERO POOR |
AT SAMPLE |
BLOOD ABSORBERS |
POINTS LEVELS <10% AUC |
48.62 5 0 |
__________________________________________________________________________ |
HOURS COVER AT FOUR |
BLOOD LEVELS PEAKING |
PEAK C(MAX)/C(MIN) |
SUBJ 0.00 5.00 10.00 |
20.00 TIME HEIGHT AT 24.00 HOURS |
__________________________________________________________________________ |
1 48.00 |
29.38 4.16 0.00 8.00 10.67 1.26 |
2 48.00 |
9.55 0.00 0.00 5.00 5.81 2.64 |
3 48.00 |
20.25 2.55 0.00 5.00 12.59 2.82 |
4 48.00 |
19.89 0.00 0.00 12.00 8.46 1.81 |
5 36.00 |
4.17 0.00 0.00 6.00 6.16 3.42 |
6 48.00 |
17.85 4.96 0.00 11.00 11.47 3.72 |
MEAN 46.00 |
16.85 1.94 0.00 7.83 9.19 2.61 |
ST DEV 4.90 8.87 2.27 0.00 3.06 2.83 0.94 |
CV (%) 0.11 0.53 1.17 0.00 0.39 0.31 0.36 |
BASED ON MEAN BLOOD LEVEL CURVE |
MEAN 48.00 |
17.87 0.00 0.00 10.00 7.87 1.91 |
__________________________________________________________________________ |
*Coefficient of variation |
**Area under the curve |
It was found that a 600 mg single dose of theophylline pellets prepared according to Example 3 in tablet form had a similar plasma level AUC (area under the curve) (175 mcg h/ml) as a 600 mg single dose of each of THEO-DUR (176.5 mcg h/ml) and UNIPHYLLIN UNICONTIN (186.9 mcg h/ml).
The theophylline prepared according to Example 3 had the lowest peak plasma level (Cmax) at the latest peak time (tmax) as shown in Table 5.
TABLE 5 |
______________________________________ |
Cmax (mcg/ml) |
tmax (h) |
______________________________________ |
Composition of 8.0 10.7 |
Example 3 |
THEO-DUR 10.1 8.5 |
UNIPHYLLIN 9.2 7.8 |
UNICONTIN |
______________________________________ |
Furthermore, the theophylline prepared according to Example 3 showed the lowest single-dose peak to trough plasma concentration ratio (Cmax/Cmin at 24 hours); Composition according to Example 3=1.98; THEO-DUR=3.85; and UNIPHYLLIN UNICONTIN=2.61.
In terms of variability, the theophylline prepared according to Example 3 showed the lowest inter subject variability in plasma level AUC (area under the curve); Composition according to Example 3 % CV=23.4; THEO-DUR % CV=27.0; and UNIPHYLLIN UNICONTIN % CV=38.6.
It will be appreciated from the foregoing description that the pellets according to the invention are more readily absorbed than conventional sustained release forms of theophylline with a similar rate of release.
Panoz, Donald E., Geoghegan, Edward J.
Patent | Priority | Assignee | Title |
10039717, | Dec 10 2002 | Nortec Development Associates, Inc. | Method of preparing biologically active formulations |
10646444, | Dec 10 2002 | Nortec Development Associates, Inc. | Method of preparing biologically formulations active |
5296236, | Sep 16 1988 | Recordati S.A., Chemical and Pharmaceutical Company | Controlled release therapeutic system for a liquid pharmaceutical formulations |
5320853, | May 20 1991 | AVENTISUB INC ; AVENTIS HOLDINGS INC ; Aventisub II Inc | Controlled release formulation for pharmaceutical compounds |
5395628, | Dec 28 1989 | ROEHM GMBH & CO KG | Controlled release succinic acid microcapsules coated with aqueous acrylics |
5510119, | Sep 16 1988 | Recordati S.A., Chemical and Pharmaceuticl Company | Controlled release therapeutic system for liquid pharmaceutical formulations |
5700484, | Dec 16 1994 | Nestec S.A. | Sustained release microparticulate caffeine formulation |
5744164, | Dec 16 1994 | Nestec S.A. | Sustained release microparticulate caffeine formulation |
5766623, | Mar 25 1996 | STATE OF OREGON ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY, THE | Compactable self-sealing drug delivery agents |
6066339, | Oct 17 1997 | Alkermes Pharma Ireland Limited | Oral morphine multiparticulate formulation |
6245913, | Jun 30 1999 | Wockhardt Europe Limited | Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimida zole hydrochloride and its conversion to omeprazole |
8133506, | Mar 12 2008 | ADARE PHARMACEUTICALS, INC | Drug delivery systems comprising weakly basic drugs and organic acids |
8329214, | Jan 17 1997 | LABORATOIRES FOURNIER S A S | Process for producing fenofibrate tablets |
8343540, | Jan 17 1997 | LABORATOIRES FOURNIER S A S | Process for producing fenofibrate tablets |
8992898, | Apr 17 2010 | LUME DEODORANT, LLC | Antiperspirants and deodorants |
9107804, | Dec 10 2002 | NORTEC DEVELOPMENT ASSOCIATES, INC | Method of preparing biologically active formulations |
9566223, | Apr 17 2010 | LUME DEODORANT, LLC | Antiperspirants and deodorants |
Patent | Priority | Assignee | Title |
2853420, | |||
3080294, | |||
3081233, | |||
3109775, | |||
3247066, | |||
3344029, | |||
3400185, | |||
3835221, | |||
3906087, | |||
3949068, | Feb 20 1964 | UAB RESEARCH FOUNDATION, THE, NON-PROFIT CORP | Pharmaceutical compositions |
4016254, | May 19 1972 | Beecham Group Limited | Pharmaceutical formulations |
4083949, | Jul 17 1973 | BYK Gulden Lomberg Chemische Fabrik GmbH | New oral form of medicament and a method for producing it |
4085214, | Oct 18 1976 | Interx Research Corporation | Stable pro-drug forms of theophylline |
4173626, | Dec 11 1978 | Merck & Co., Inc. | Sustained release indomethacin |
4248858, | Aug 09 1979 | American Home Products Corporation | Sustained release pharmaceutical compositions |
4309406, | Jul 10 1979 | American Home Products Corporation | Sustained release pharmaceutical compositions |
4324779, | Aug 28 1973 | Aventis Pharma Deutschland GmbH | Method for treating hypertonia with N-(2-furfuryl)-4-chloro-5-sulfamoyl-anthranilic acid and preparations thereof |
4367217, | Jan 12 1980 | KARL THOMAE GMBH DR | Dipyricamole sustained release forms comprising lacquer-coated particles and the preparation thereof |
4415547, | Jun 14 1982 | SANOFI S A | Sustained-release pharmaceutical tablet and process for preparation thereof |
4462991, | Mar 07 1980 | INTERx Research Corp. | Method of increasing oral absorption of polar bioactive agents |
4663150, | Apr 06 1983 | Elan Corporation P.L.C. | Sustained absorption pharmaceutical composition |
4710384, | Jul 28 1986 | BIO-DAR LTD | Sustained release tablets made from microcapsules |
CA1178204, | |||
EP32562, | |||
EP36145, | |||
EP69958, | |||
EP92060, | |||
GB2025227, | |||
GB2067073A, | |||
WO8300284, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Jan 16 1987 | Eland Corporation P.L.C. | (assignment on the face of the patent) | / |
Date | Maintenance Fee Events |
Jul 15 1991 | ASPN: Payor Number Assigned. |
Sep 14 1992 | M183: Payment of Maintenance Fee, 4th Year, Large Entity. |
Sep 17 1996 | M184: Payment of Maintenance Fee, 8th Year, Large Entity. |
Oct 10 2000 | M185: Payment of Maintenance Fee, 12th Year, Large Entity. |
Date | Maintenance Schedule |
Apr 11 1992 | 4 years fee payment window open |
Oct 11 1992 | 6 months grace period start (w surcharge) |
Apr 11 1993 | patent expiry (for year 4) |
Apr 11 1995 | 2 years to revive unintentionally abandoned end. (for year 4) |
Apr 11 1996 | 8 years fee payment window open |
Oct 11 1996 | 6 months grace period start (w surcharge) |
Apr 11 1997 | patent expiry (for year 8) |
Apr 11 1999 | 2 years to revive unintentionally abandoned end. (for year 8) |
Apr 11 2000 | 12 years fee payment window open |
Oct 11 2000 | 6 months grace period start (w surcharge) |
Apr 11 2001 | patent expiry (for year 12) |
Apr 11 2003 | 2 years to revive unintentionally abandoned end. (for year 12) |